Kesheng Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kesheng Dai has a total of 242 co-authors. Here are the top co-authors by number of shared publications:
Rong Yan
Jiangsu Institute of Hematology, Cyrus Tang Medical Institute, The First Affiliated Hospital and Collaborative Innovation Center of Hematology, Soochow University, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, National Clinical Research Center for Hematological Diseases, 215006, Suzhou, China
21 shared publicationsLili Zhao
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
11 shared publicationsMengnan Yang
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
11 shared publicationsKangxi Zhou
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
10 shared publicationsRenping Hu
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
10 shared publicationsChanggeng Ruan
Jiangsu Institute of Hematology, Cyrus Tang Medical Institute, The First Affiliated Hospital and Collaborative Innovation Center of Hematology, Suzhou Medical College, Soochow University, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, National Clinical Research Center for Hematological Diseases, Suzhou, China
8 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1256
Potential Role of Contact Pathway Factors in Catheter-Related Thrombosis: Emerging Evidence and Therapeutic Strategies
The catheter is among the most commonly used blood-contacting medical devices, but its use can induce surface-mediated coagulation activation, leading to catheter-related thrombosis (CRT). The occurrence of CRT causes venous thromboembolism and catheter malfunction, but current antithrombotic strategies have unsatisfactory efficacy and safety profiles. Here, we review recent advances in the understanding of the pathology of CRT, particularly the roles of the contact pathway factors, and promising novel therapeutic options. Recent studies using genetically modified animals, factor-deficient plasmas, specific inhibitors and purified systems demonstrated an important contribution of contact pathway factors XII and XI to catheter-related blood clotting. Accordingly, contact pathway inhibition has efficacy comparable to that of heparins in mitigating catheter-related coagulation or intraluminal occlusion in various in vitro and animal models, while having lower bleeding risk. Early human studies suggest potential thromboprotective effects of FXI inhibition in catheter placement and hemodialysis settings. However, inhibition of factors XII or XI may impair the defense against infection or disturb normal cardiac function, respectively. Larger human trials are needed to further confirm the efficacy and safety of these contact pathway inhibitors, and to explore whether low-dose combinations of contact pathway inhibitors with heparins are more effective for CRT protection.
- 29 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1256
Open AccessPotential Role of Contact Pathway Factors in Catheter-Related Thrombosis: Emerging Evidence and Therapeutic Strategies
The catheter is among the most commonly used blood-contacting medical devices, but its use can induce surface-mediated coagulation activation, leading to catheter-related thrombosis (CRT). The occurrence of CRT causes venous thromboembolism and catheter malfunction, but current antithrombotic strategies have unsatisfactory efficacy and safety profiles. Here, we review recent advances in the understanding of the pathology of CRT, particularly the roles of the contact pathway factors, and promising novel therapeutic options. Recent studies using genetically modified animals, factor-deficient plasmas, specific inhibitors and purified systems demonstrated an important contribution of contact pathway factors XII and XI to catheter-related blood clotting. Accordingly, contact pathway inhibition has efficacy comparable to that of heparins in mitigating catheter-related coagulation or intraluminal occlusion in various in vitro and animal models, while having lower bleeding risk. Early human studies suggest potential thromboprotective effects of FXI inhibition in catheter placement and hemodialysis settings. However, inhibition of factors XII or XI may impair the defense against infection or disturb normal cardiac function, respectively. Larger human trials are needed to further confirm the efficacy and safety of these contact pathway inhibitors, and to explore whether low-dose combinations of contact pathway inhibitors with heparins are more effective for CRT protection.
- 11 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (8)
Platelet RIP2 Limits Dense Granule Release and Thrombosis via DOCK8-Cdc42
BACKGROUND: RIP2 (receptor-interacting protein kinase 2) is an essential mediator of inflammation and innate immunity downstream of PRRs (pattern recognition receptors). Platelets express RIP2, while its role in platelet activation, thrombosis, and myocardial infarction, and whether these effects are mediated through the PRR pathway, is unknown. METHODS: In vitro assays of platelet aggregation, dense and α-granule secretion, spreading, and clot retraction, along with an ex vivo microfluidic whole blood perfusion assay, and in vivo models of FeCl 3 -induced mesenteric arteriolar thrombosis and ischemia/reperfusion myocardial infarction, were used to assess the impact of RIP2 deficiency on platelet function. Immunoprecipitation followed by liquid chromatography-tandem mass spectrometry was performed to elucidate the mechanism by which RIP2 limits dense granule secretion in platelets. Furthermore, RIP2 expression levels in platelets from healthy donors and patients with coronary artery disease were measured by Western blotting to evaluate their clinical relevance. RESULTS: Here, we show that RIP2 deficiency enhances platelet dense granule secretion in response to GPIb (platelet glycoprotein Ib) and GPVI (platelet glycoprotein VI) activation; platelet aggregation in whole blood and adhesion under arterial shear are also increased. Consistently, RIP2 inhibitor WEHI-345 potentiates human platelet dense granule secretion and inhibits RIP2 phosphorylation induced by thrombin and collagen. These phenotypes are translated into shorter bleeding time and accelerated FeCl 3 -induced arterial thrombosis. Importantly, platelets from patients with coronary artery disease and mice with atherosclerosis express lower RIP2, and RIP2 deficiency worsens myocardial infarction and cardiac function in a mouse ischemia/reperfusion model. Mechanistically, we found that platelets express DOCK8 (dedicator of cytogenesis protein 8), which is sequestered by p-RIP2 (phosphorylated RIP2), causing inhibition of Cdc42 (cell division cycle 42) activation and subsequent dense granule release. CONCLUSIONS: RIP2 restrains platelet activation and thrombosis, thereby mitigating myocardial infarction. We identify a novel PRR-independent pathway, p-RIP2-DOCK8-Cdc42, which suppresses dense granule release downstream of GPIb and GPVI. Targeting the platelet RIP2 pathway may offer a therapeutic strategy against atherothrombotic diseases from early atherosclerosis to arterial thrombosis and myocardial infarction.
- 11 June 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (8)
Platelet RIP2 Limits Dense Granule Release and Thrombosis via DOCK8-Cdc42
BACKGROUND: RIP2 (receptor-interacting protein kinase 2) is an essential mediator of inflammation and innate immunity downstream of PRRs (pattern recognition receptors). Platelets express RIP2, while its role in platelet activation, thrombosis, and myocardial infarction, and whether these effects are mediated through the PRR pathway, is unknown. METHODS: In vitro assays of platelet aggregation, dense and α-granule secretion, spreading, and clot retraction, along with an ex vivo microfluidic whole blood perfusion assay, and in vivo models of FeCl 3 -induced mesenteric arteriolar thrombosis and ischemia/reperfusion myocardial infarction, were used to assess the impact of RIP2 deficiency on platelet function. Immunoprecipitation followed by liquid chromatography-tandem mass spectrometry was performed to elucidate the mechanism by which RIP2 limits dense granule secretion in platelets. Furthermore, RIP2 expression levels in platelets from healthy donors and patients with coronary artery disease were measured by Western blotting to evaluate their clinical relevance. RESULTS: Here, we show that RIP2 deficiency enhances platelet dense granule secretion in response to GPIb (platelet glycoprotein Ib) and GPVI (platelet glycoprotein VI) activation; platelet aggregation in whole blood and adhesion under arterial shear are also increased. Consistently, RIP2 inhibitor WEHI-345 potentiates human platelet dense granule secretion and inhibits RIP2 phosphorylation induced by thrombin and collagen. These phenotypes are translated into shorter bleeding time and accelerated FeCl 3 -induced arterial thrombosis. Importantly, platelets from patients with coronary artery disease and mice with atherosclerosis express lower RIP2, and RIP2 deficiency worsens myocardial infarction and cardiac function in a mouse ischemia/reperfusion model. Mechanistically, we found that platelets express DOCK8 (dedicator of cytogenesis protein 8), which is sequestered by p-RIP2 (phosphorylated RIP2), causing inhibition of Cdc42 (cell division cycle 42) activation and subsequent dense granule release. CONCLUSIONS: RIP2 restrains platelet activation and thrombosis, thereby mitigating myocardial infarction. We identify a novel PRR-independent pathway, p-RIP2-DOCK8-Cdc42, which suppresses dense granule release downstream of GPIb and GPVI. Targeting the platelet RIP2 pathway may offer a therapeutic strategy against atherothrombotic diseases from early atherosclerosis to arterial thrombosis and myocardial infarction.
- 4 June 2026
- Published by Elsevier in Translational Research
- Vol. 294, 10-21
High-concentration estradiol promotes platelet activation and thrombosis through Src-ADP axis
- 4 June 2026
- Published by Elsevier in Translational Research
- Vol. 294, 10-21
High-concentration estradiol promotes platelet activation and thrombosis through Src-ADP axis
- Open Access
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1734694
Role of albumin in regulating platelet function
Introduction: Hypoproteinemia, which occurs in diverse clinical conditions, can cause a range of complications such as thrombosis, which is among the most serious and potentially life-threatening. Albumin is a widely utilized clinical therapeutic agent; however, research regarding its regulatory effects on thrombosis remains limited, and existing clinical evidence presents conflicting findings. The precise mechanisms whereby albumin affects platelet thrombus formation require further investigation. Methods: After co-incubating albumin with platelets, various platelet function experiments were carried out. The participation of signaling pathways and protein structures in the mechanism was verified by means of Western blot technology, protein charge neutralization, and over expression of molecules. Validation was also conducted through the construction of animal models. Results: Albumin significantly inhibited platelet thrombus formation in a murine model of hypoproteinemia without inducing hemorrhagic risk. Platelet aggregation, integrin activation on the membrane surface, and ATP release induced by various agonists were all inhibited. Transmission electron microscopy and fluorescence confocal microscopy revealed that albumin could suppress granule release, alter granule distribution within platelets, and inhibit platelet spreading. Furthermore, albumin was found to reduce the phosphorylation levels of PKC and Akt in the platelet activation signaling pathway. By neutralizing the surface negative charge of albumin and adding cationic surfactants such as quaternary ammonium salts, we confirmed that the surface negative charge of albumin was critical to the inhibition of platelet aggregation and granule release. Conclusion: Albumin can inhibit platelet activation and thrombus formation through the negatively charged surface residues and by modulating the PKC and Akt signaling pathways.
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1734694
Open AccessRole of albumin in regulating platelet function
Introduction: Hypoproteinemia, which occurs in diverse clinical conditions, can cause a range of complications such as thrombosis, which is among the most serious and potentially life-threatening. Albumin is a widely utilized clinical therapeutic agent; however, research regarding its regulatory effects on thrombosis remains limited, and existing clinical evidence presents conflicting findings. The precise mechanisms whereby albumin affects platelet thrombus formation require further investigation. Methods: After co-incubating albumin with platelets, various platelet function experiments were carried out. The participation of signaling pathways and protein structures in the mechanism was verified by means of Western blot technology, protein charge neutralization, and over expression of molecules. Validation was also conducted through the construction of animal models. Results: Albumin significantly inhibited platelet thrombus formation in a murine model of hypoproteinemia without inducing hemorrhagic risk. Platelet aggregation, integrin activation on the membrane surface, and ATP release induced by various agonists were all inhibited. Transmission electron microscopy and fluorescence confocal microscopy revealed that albumin could suppress granule release, alter granule distribution within platelets, and inhibit platelet spreading. Furthermore, albumin was found to reduce the phosphorylation levels of PKC and Akt in the platelet activation signaling pathway. By neutralizing the surface negative charge of albumin and adding cationic surfactants such as quaternary ammonium salts, we confirmed that the surface negative charge of albumin was critical to the inhibition of platelet aggregation and granule release. Conclusion: Albumin can inhibit platelet activation and thrombus formation through the negatively charged surface residues and by modulating the PKC and Akt signaling pathways.
- Open Access
Glycoprotein Ibα‐Dependent Platelet Activation is Essential for Tumor Cell–Platelet Interaction and Experimental Metastasis
Metastasis is the main cause of cancer‐related deaths and the biggest challenge in improving cancer prognosis. Platelet–tumor cell aggregates are a prerequisite for hematogenous metastasis. However, the internal relation and molecular mechanism of platelets and their receptor glycoprotein (GP) Ibα in platelet–tumor cell interaction and metastasis remain elusive. Here, we find that in the absence of the full‐length GPIbα or its cytoplasmic tail, platelets maintain a more resting state and exhibit reduced tumor cell‐induced platelet activation. The deficiency of the cytoplasmic tail of GPIbα inhibits tumor cell–platelet interaction, platelet‐induced tumor cell migration and invasion, and metastasis. Using a state‐of‐the‐art spinning disk intravital microscopy, we observe a rapid accumulation of platelets on tumor cells, forming numerous tumor cell–platelet aggregates in vivo. We also find that the cytoplasmic tail of GPIbα regulates the tumor cell‐induced platelet protein kinase C‐α (PKCα) activation, and both the pharmacological inhibition and genetic ablation of platelet PKCα attenuate tumor cell‐induced platelet activation, tumor cell–platelet interaction, tumor cell migration and invasion, and metastasis. Overall, our findings reveal for the first time that GPIbα promotes experimental metastasis through its cytoplasmic tail‐regulated platelet activation, and suggest a potential target to regulate tumor hematogenous metastasis.
Open AccessGlycoprotein Ibα‐Dependent Platelet Activation is Essential for Tumor Cell–Platelet Interaction and Experimental Metastasis
Metastasis is the main cause of cancer‐related deaths and the biggest challenge in improving cancer prognosis. Platelet–tumor cell aggregates are a prerequisite for hematogenous metastasis. However, the internal relation and molecular mechanism of platelets and their receptor glycoprotein (GP) Ibα in platelet–tumor cell interaction and metastasis remain elusive. Here, we find that in the absence of the full‐length GPIbα or its cytoplasmic tail, platelets maintain a more resting state and exhibit reduced tumor cell‐induced platelet activation. The deficiency of the cytoplasmic tail of GPIbα inhibits tumor cell–platelet interaction, platelet‐induced tumor cell migration and invasion, and metastasis. Using a state‐of‐the‐art spinning disk intravital microscopy, we observe a rapid accumulation of platelets on tumor cells, forming numerous tumor cell–platelet aggregates in vivo. We also find that the cytoplasmic tail of GPIbα regulates the tumor cell‐induced platelet protein kinase C‐α (PKCα) activation, and both the pharmacological inhibition and genetic ablation of platelet PKCα attenuate tumor cell‐induced platelet activation, tumor cell–platelet interaction, tumor cell migration and invasion, and metastasis. Overall, our findings reveal for the first time that GPIbα promotes experimental metastasis through its cytoplasmic tail‐regulated platelet activation, and suggest a potential target to regulate tumor hematogenous metastasis.
- 1 May 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (5) , 778-791
BAD-Glucokinase Axis Regulates Platelet Activation and Thrombosis
BACKGROUND: BAD (Bcl2-associated death promoter), a member of the Bcl2 proapoptotic family, promotes cell apoptosis by sequestering the prosurvival proteins Bcl-XL and Bcl2 from the proapoptotic proteins BAK (Bcl2 homologous antagonist/killer) and BAX (Bcl2-associated X protein) in nucleated cells. BAD is also expressed in platelets, playing a role in regulating platelet lifespan, apoptosis, and clearance. However, whether BAD regulates platelet activation and arterial thrombosis remains unclear. METHODS: The role of BAD in platelet activation and arterial thrombosis was investigated using BAD-deficient mice ( Bad −/− ), in vitro functional studies, and arterial thrombosis models. The regulatory effect of BAD on platelet energy metabolism was detected using a Seahorse Extracellular Flux Analyzer. The regulatory effect of BAD on glucokinase was investigated by coimmunoprecipitation and activity measurement. The glucokinase heterozygous knockout mice ( Gck +/− ) and activator were used to study its role in platelet activation. RESULTS: BAD-deficient mice ( Bad −/− ) and wild-type mice transfused with Bad −/− platelets displayed prolonged tail bleeding and arterial occlusion times. Bad −/− platelets exhibited decreased aggregation in response to stimulations by proteinase-activated receptor 4-activating peptide, thrombin, and U46619. Furthermore, BAD ablation suppressed platelet integrin α IIb β 3 activation, granule secretion, and clot retraction induced by these agonists. Mechanistically, BAD interacted with glucokinase, and BAD deficiency resulted in decreased platelet glucokinase activity, mitochondrial oxidative phosphorylation, and mitochondrial ATP production. The partial loss of glucokinase ( Gck +/− ) phenocopied platelet function defects caused by BAD deficiency, and a glucokinase activator rescued the impaired mitochondrial ATP production and function of Bad −/− platelets. Additionally, the glucokinase activator enhanced human platelet activation. CONCLUSIONS: Our findings demonstrate the critical role of the BAD-glucokinase axis in platelet activation and thrombosis, suggesting a potential target for antithrombotic therapy.
- 1 May 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (5) , 778-791
BAD-Glucokinase Axis Regulates Platelet Activation and Thrombosis
BACKGROUND: BAD (Bcl2-associated death promoter), a member of the Bcl2 proapoptotic family, promotes cell apoptosis by sequestering the prosurvival proteins Bcl-XL and Bcl2 from the proapoptotic proteins BAK (Bcl2 homologous antagonist/killer) and BAX (Bcl2-associated X protein) in nucleated cells. BAD is also expressed in platelets, playing a role in regulating platelet lifespan, apoptosis, and clearance. However, whether BAD regulates platelet activation and arterial thrombosis remains unclear. METHODS: The role of BAD in platelet activation and arterial thrombosis was investigated using BAD-deficient mice ( Bad −/− ), in vitro functional studies, and arterial thrombosis models. The regulatory effect of BAD on platelet energy metabolism was detected using a Seahorse Extracellular Flux Analyzer. The regulatory effect of BAD on glucokinase was investigated by coimmunoprecipitation and activity measurement. The glucokinase heterozygous knockout mice ( Gck +/− ) and activator were used to study its role in platelet activation. RESULTS: BAD-deficient mice ( Bad −/− ) and wild-type mice transfused with Bad −/− platelets displayed prolonged tail bleeding and arterial occlusion times. Bad −/− platelets exhibited decreased aggregation in response to stimulations by proteinase-activated receptor 4-activating peptide, thrombin, and U46619. Furthermore, BAD ablation suppressed platelet integrin α IIb β 3 activation, granule secretion, and clot retraction induced by these agonists. Mechanistically, BAD interacted with glucokinase, and BAD deficiency resulted in decreased platelet glucokinase activity, mitochondrial oxidative phosphorylation, and mitochondrial ATP production. The partial loss of glucokinase ( Gck +/− ) phenocopied platelet function defects caused by BAD deficiency, and a glucokinase activator rescued the impaired mitochondrial ATP production and function of Bad −/− platelets. Additionally, the glucokinase activator enhanced human platelet activation. CONCLUSIONS: Our findings demonstrate the critical role of the BAD-glucokinase axis in platelet activation and thrombosis, suggesting a potential target for antithrombotic therapy.
- Open Access
- 10 February 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (3) , e70403
Iloprost Concentration‐Dependently Attenuates Platelet Function and Apoptosis by Elevating PKA Activity
Iloprost, a prostacyclin (PGI2) analogue, stimulates the IP receptor (PTGIR) to interact with the Gsα β/γ complex, leading to the activation of adenylate cyclase, which enzyme produces the second messenger cAMP. Elevation in cAMP triggers intracellular signalling events and regulates a wide variety of cellular activities. Thus, we evaluated the effects of Iloprost on platelet function and apoptosis and in vivo haemostasis and thrombosis, as well as the underlying mechanisms. Firstly, we showed that Iloprost concentration‐dependently inhibited agonist‐induced P‐selectin exposure, integrin αIIbβ3 activation, platelet aggregation, ATP release, platelet spreading, and clot retraction. Moreover, Iloprost dose‐dependently inhibited FeCl3‐induced mouse mesenteric arteriole thrombosis and markedly prolonged the tail bleeding time. Iloprost also concentration‐dependently inhibited mitochondrial membrane potential (ΔΨm) depolarisation and phosphatidylserine (PS) externalisation in platelets, thereby inhibiting platelet apoptosis, and Iloprost at concentrations lower than 2 nM inhibited only platelet apoptosis but not platelet function. Importantly, Iloprost at low doses markedly elevated peripheral platelet counts in GPIbα antibody‐induced immune thrombocytopenia (ITP). Mechanistic studies showed that Iloprost concentration‐dependently antagonised agonist‐induced decline of protein kinase A (PKA) activity and elevation of cytoplasmic Ca2+ in platelets, thereby attenuating platelet activation and aggregation. Elevation in PKA activity inhibited dephosphorylation of proapoptotic protein BAD and reduced caspase‐3 activity, thus retarding platelet apoptosis. These data demonstrate that Iloprost dose‐dependently inhibits platelet function and apoptosis by elevating PKA activity. Moderate‐dose Iloprost impairs haemostasis and thrombosis via suppression of platelet function, and low‐dose Iloprost elevates peripheral platelet levels by inhibiting platelet apoptosis while having no effects on platelet function.
- 10 February 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (3) , e70403
Open AccessIloprost Concentration‐Dependently Attenuates Platelet Function and Apoptosis by Elevating PKA Activity
Iloprost, a prostacyclin (PGI2) analogue, stimulates the IP receptor (PTGIR) to interact with the Gsα β/γ complex, leading to the activation of adenylate cyclase, which enzyme produces the second messenger cAMP. Elevation in cAMP triggers intracellular signalling events and regulates a wide variety of cellular activities. Thus, we evaluated the effects of Iloprost on platelet function and apoptosis and in vivo haemostasis and thrombosis, as well as the underlying mechanisms. Firstly, we showed that Iloprost concentration‐dependently inhibited agonist‐induced P‐selectin exposure, integrin αIIbβ3 activation, platelet aggregation, ATP release, platelet spreading, and clot retraction. Moreover, Iloprost dose‐dependently inhibited FeCl3‐induced mouse mesenteric arteriole thrombosis and markedly prolonged the tail bleeding time. Iloprost also concentration‐dependently inhibited mitochondrial membrane potential (ΔΨm) depolarisation and phosphatidylserine (PS) externalisation in platelets, thereby inhibiting platelet apoptosis, and Iloprost at concentrations lower than 2 nM inhibited only platelet apoptosis but not platelet function. Importantly, Iloprost at low doses markedly elevated peripheral platelet counts in GPIbα antibody‐induced immune thrombocytopenia (ITP). Mechanistic studies showed that Iloprost concentration‐dependently antagonised agonist‐induced decline of protein kinase A (PKA) activity and elevation of cytoplasmic Ca2+ in platelets, thereby attenuating platelet activation and aggregation. Elevation in PKA activity inhibited dephosphorylation of proapoptotic protein BAD and reduced caspase‐3 activity, thus retarding platelet apoptosis. These data demonstrate that Iloprost dose‐dependently inhibits platelet function and apoptosis by elevating PKA activity. Moderate‐dose Iloprost impairs haemostasis and thrombosis via suppression of platelet function, and low‐dose Iloprost elevates peripheral platelet levels by inhibiting platelet apoptosis while having no effects on platelet function.
- 7 November 2024
- Published by Elsevier in Thrombosis Research
- Vol. 244, 109210
The role of protein kinase C and the glycoprotein Ibα cytoplasmic tail in anti-glycoprotein Ibα antibody-induced platelet apoptosis and thrombocytopenia
- 7 November 2024
- Published by Elsevier in Thrombosis Research
- Vol. 244, 109210
The role of protein kinase C and the glycoprotein Ibα cytoplasmic tail in anti-glycoprotein Ibα antibody-induced platelet apoptosis and thrombocytopenia
- Open Access
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11548
Platelet Glycoprotein Ibα Cytoplasmic Tail Exacerbates Thrombosis During Bacterial Sepsis
Septic patients, coupling severe disseminated intravascular coagulation (DIC) and thrombocytopenia, have poor prognoses and higher mortality. The platelet glycoprotein Ibα (GPIbα) is involved in thrombosis, hemostasis, and inflammation response. However, it remains unclear whether the GPIbα cytoplasmic tail regulates sepsis-mediated platelet activation and inflammation, especially in Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) infections. Using a mouse model of S. aureus-induced bacteremia, we found that both 10 amino acids of GPIbα C-terminal sequence deficiency and pharmacologic inhibition of protein kinase C (PKC) alleviated pathogenesis by diminishing platelet activation and aggregate formation. Furthermore, the GPIbα cytoplasmic tail promoted the phagocytosis of platelets by Kupffer cells in vivo. The genetically deficient GPIbα cytoplasmic tail also downregulated inflammatory cytokines and reduced liver damage, ultimately improving the survival rate of the septic mice. Our results illustrate that the platelet GPIbα cytoplasmic domain exacerbates excessive platelet activation and inflammation associated with sepsis through a PKC-dependent pathway. Thus, our findings provide insights for the development of effective therapeutic strategies using PKC inhibitor treatment against bacterial infection.
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11548
Open AccessPlatelet Glycoprotein Ibα Cytoplasmic Tail Exacerbates Thrombosis During Bacterial Sepsis
Septic patients, coupling severe disseminated intravascular coagulation (DIC) and thrombocytopenia, have poor prognoses and higher mortality. The platelet glycoprotein Ibα (GPIbα) is involved in thrombosis, hemostasis, and inflammation response. However, it remains unclear whether the GPIbα cytoplasmic tail regulates sepsis-mediated platelet activation and inflammation, especially in Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) infections. Using a mouse model of S. aureus-induced bacteremia, we found that both 10 amino acids of GPIbα C-terminal sequence deficiency and pharmacologic inhibition of protein kinase C (PKC) alleviated pathogenesis by diminishing platelet activation and aggregate formation. Furthermore, the GPIbα cytoplasmic tail promoted the phagocytosis of platelets by Kupffer cells in vivo. The genetically deficient GPIbα cytoplasmic tail also downregulated inflammatory cytokines and reduced liver damage, ultimately improving the survival rate of the septic mice. Our results illustrate that the platelet GPIbα cytoplasmic domain exacerbates excessive platelet activation and inflammation associated with sepsis through a PKC-dependent pathway. Thus, our findings provide insights for the development of effective therapeutic strategies using PKC inhibitor treatment against bacterial infection.
- 1 October 2024
- Vol. 32 (5) , 1503-1508
[Regulation of Reactive Oxygen Species on Platelet Activation and Apoptosis].
To investigate how reactive oxygen species (ROS) regulates the signal transduction of platelet activation and apoptosis, and to explore the relationship between platelet activation and apoptosis. Platelets were directly stimulated with thrombin or pretreated with ROS inhibitor N-acetylcysteine (NAC) before being stimulated with thrombin, and then flow cytometry was used to detect the effects of thrombin and NAC on P-selectin expression, αⅡbβ3 activation, mitochondrial membrane potential depolarization, phosphatidylserine (PS) externalization, ROS expression and platelet aggregation. Thrombin could induce the production of ROS in platelets in a concentration- and time-dependent manner. 0.01 U thrombin induced ROS-dependent high degree of integrin αⅡbβ3 activation, P-selectin expression, and platelet aggregation. The platelets induced by different concentration gradients of thrombin exhibited ROS-dependent mitochondrial membrane potential depolarization and PS externalization in platelets. After induction with thrombin for 30 min, the activation of integrin αⅡbβ3 in platelets reached its maximum level, and after 60 minutes, the depolarization of mitochondrial membrane potential in platelets reached its maximum level. However, the expression of P-selectin, depolarization of mitochondrial membrane potential, and platelet aggregation function were all inhibited to a certain extent when the platelets were pretreated with ROS inhibitor NAC and then induced with thrombin. When platelets are induced by thrombin, ROS first regulates the activation of platelets, and then regulates the apoptosis of platelets. Both platelet activation and apoptosis depend on the production of ROS in platelets, and the signals of activation and apoptosis occur orderly. Inhibiting the ROS signal in platelets can effectively inhibit the activation and apoptosis of platelets.
- 1 October 2024
- Vol. 32 (5) , 1503-1508
[Regulation of Reactive Oxygen Species on Platelet Activation and Apoptosis].
To investigate how reactive oxygen species (ROS) regulates the signal transduction of platelet activation and apoptosis, and to explore the relationship between platelet activation and apoptosis. Platelets were directly stimulated with thrombin or pretreated with ROS inhibitor N-acetylcysteine (NAC) before being stimulated with thrombin, and then flow cytometry was used to detect the effects of thrombin and NAC on P-selectin expression, αⅡbβ3 activation, mitochondrial membrane potential depolarization, phosphatidylserine (PS) externalization, ROS expression and platelet aggregation. Thrombin could induce the production of ROS in platelets in a concentration- and time-dependent manner. 0.01 U thrombin induced ROS-dependent high degree of integrin αⅡbβ3 activation, P-selectin expression, and platelet aggregation. The platelets induced by different concentration gradients of thrombin exhibited ROS-dependent mitochondrial membrane potential depolarization and PS externalization in platelets. After induction with thrombin for 30 min, the activation of integrin αⅡbβ3 in platelets reached its maximum level, and after 60 minutes, the depolarization of mitochondrial membrane potential in platelets reached its maximum level. However, the expression of P-selectin, depolarization of mitochondrial membrane potential, and platelet aggregation function were all inhibited to a certain extent when the platelets were pretreated with ROS inhibitor NAC and then induced with thrombin. When platelets are induced by thrombin, ROS first regulates the activation of platelets, and then regulates the apoptosis of platelets. Both platelet activation and apoptosis depend on the production of ROS in platelets, and the signals of activation and apoptosis occur orderly. Inhibiting the ROS signal in platelets can effectively inhibit the activation and apoptosis of platelets.